Article Versions Notes

Tsai C-L, Changchien C-Y, Chen Y, Lai C-R, Chen T-M, Chang H-H, Tsai W-C, Tsai Y-L, Tsai H-C, Lin H-Y, et al. Survival Benefit of Statin with Anti-Angiogenesis Efficacy in Lung Cancer-Associated Pleural Fluid through FXR Modulation. Cancers. 2022; 14(11):2765. https://doi.org/10.3390/cancers14112765

Tsai, Chen-Liang, Chih-Ying Changchien, Ying Chen, Chine-Rui Lai, Tzu-Min Chen, Hsin-Han Chang, Wen-Chiuan Tsai, Yu-Ling Tsai, Hao-Chung Tsai, Hung-Yi Lin, and et al. 2022. "Survival Benefit of Statin with Anti-Angiogenesis Efficacy in Lung Cancer-Associated Pleural Fluid through FXR Modulation" Cancers 14, no. 11: 2765. https://doi.org/10.3390/cancers14112765

Tsai, C.-L., Changchien, C.-Y., Chen, Y., Lai, C.-R., Chen, T.-M., Chang, H.-H., Tsai, W.-C., Tsai, Y.-L., Tsai, H.-C., Lin, H.-Y., Wang, C.-Y., Shen, M.-S., & Lin, Y.-H. (2022). Survival Benefit of Statin with Anti-Angiogenesis Efficacy in Lung Cancer-Associated Pleural Fluid through FXR Modulation. Cancers, 14(11), 2765. https://doi.org/10.3390/cancers14112765